Clinical trials: LBCL
Large B-Cell Lymphoma (LBCL)
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons.
- Trial name
- NCT07461831
- Testing
- CD19/CD22 bispecific CAR-T cells
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Tongren Hospital